Positive new data for Jerini's icatibant
Germany's Jerini has released positive Phase II data showing the potential utility of its icatibant (JE049) as a treatment for acute attacks of hereditary angioedema.
In the European trial, a single dose of icatibant was administered intravenously to eight patients. Angioedema symptoms resolved rapidly in all subjects, and the treatment response was sustained over the duration of the study, noted the company. Furthermore, the agent was well-tolerated by all patients.
Icatibant is a bradykinin 2 receptor antagonist, and has been granted Orphan Drug designation in the USA and in the European Union for the treatment of angioedema (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze